(CercleFinance.com) – Novavax publishes a total turnover of 424 M$ for the 2nd quarter, an increase of nearly 130% compared to the same period a year earlier.
The laboratory recorded a net profit of $58 million over the period, far from the loss of $510 million recorded twelve months earlier.
Diluted EPS stands at $0.58 compared to -$6.53 in the 2nd quarter of 2022.
Novavax anticipates 2023 revenue of between $1.3 billion and $1.5 billion, compared to between $1.4 and $1.5 billion in the previous estimate.
The laboratory specifies that it has launched its application for the marketing of its updated Covid vaccine in the United States, in the EU and in Canada.
“We continue to work to derive additional value from our pipeline and technology and advance our combined COVID-influenza vaccine candidate to the next stage and into late-stage development,” added John C. Jacobs, Director .
Copyright © 2023 CercleFinance.com. All rights reserved.
Did you like this article ? Share it with your friends with the buttons below.
